Replies to post #91864 on Biotech Values

[DewDiligence]

ONXX:

the only reason I can find for why Love was hired at Onyx is because both he and Onyx's CEO are African-American.

Why do you say that? Being a bad CEO at one company does not necessarily make someone unqualified to be a CMO at another company. A CMO position might be exactly what Love is suited for.

[rkrw]

I hate to say it but that's an obnoxious and bigoted thing to say.

Here's his background.

Most recently, Dr. Love was President, Chief Executive Officer, and Chairman of the Board of Directors of the biotechnology company Nuvelo, Inc. He grew Nuvelo into a late-stage development company focused on acute cardiovascular disease, cancer, and other debilitating medical conditions. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Previously, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee.

Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, Dr. Love joined the faculty of Massachusetts General in the department of cardiology. He currently serves on the board of directors of Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens' Oversight Committee.